For NHL Players, More Fighting on the Ice Is Linked to Shorter Lives
THURSDAY, May 11, 2023 (HealthDay News) — Fighting is par for the course in professional ice hockey, but a new study raises the question of whether it is shortening some players’ lives.The study, of hundreds of National Hockey League (NHL) players, f…
Learn MoreWomen Have About 12-Year Delay in Onset of Atherosclerosis
THURSDAY, May 11, 2023 (HealthDay News) — Women have an approximately 12-year delay in the onset of coronary atherosclerosis, but those in the highest atherosclerotic burden group have a higher risk for major adverse cardiovascular events (MACE), acc…
Learn MoreChronic Pain Disparity Seen Among Some Sexual Minority Populations
THURSDAY, May 11, 2023 (HealthDay News) — Sexual minority adults who identify as bisexual or “something else” have a significantly higher prevalence of chronic pain than gay/lesbian or straight adults, according to a study published online March 30 i…
Learn MoreOverweight, Obesity in Early, Middle Adulthood Increases Risk for GI Cancers
THURSDAY, May 11, 2023 (HealthDay News) — Overweight and obese body mass indices (BMIs) in early and middle adulthood are associated with a higher risk for colorectal cancer (CRC) and non-CRC gastrointestinal (GI) cancers, according to a study publis…
Learn MoreRSV in First Year of Life Tied to Risk for Childhood Asthma
THURSDAY, May 11, 2023 (HealthDay News) — Among healthy, term infants, not being infected with respiratory syncytial virus (RSV) in the first year of life is associated with a substantially lower risk for developing childhood asthma, according to a s…
Learn MoreHormone Preparations Tied to Increased Bone Mineral Density in Postmenopausal Women
THURSDAY, May 11, 2023 (HealthDay News) — Hormone preparations are associated with an increase in lumbar spine bone mineral density (BMD) in postmenopausal women, according to a study published online May 2 in Menopause.Yiran Wang, M.D., and Chao Sun…
Learn MoreCabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 (HealthDay News) — Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with previously untreated, advanced renal-…
Learn More